TIGIT:CD112 Homogeneous Assay Kit

Catalog #
72030
$335 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The TIGIT:CD112 Homogeneous Assay Kit is designed to measure the inhibition of human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) binding to CD112 (PVRL2/Nectin-2). The TIGIT:CD112 Homogeneous Assay Kit comes in a convenient AlphaLISA® format with purified biotinylated TIGIT, His-tagged CD112, and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing TIGIT and an inhibitor of choice is incubated with the CD112 for 60 minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.

Need us to run inhibitor screens or profile your compounds against TIGIT:CD112? Check out our Immunotherapy Biochemical Screening Services.

Synonyms
T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9 (VSIG9), and V-set and transmembrane domaincontaining protein 3 (VSTM3), PVRL2
Product Info
Storage and Usage
Citations
Assay Kit Format
AlphaLISA®
Format

UniProt #
TIGIT: Q495A1; CD112: Q92692
Background
Human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a receptor that is expressed on the surface of human T cells and NK cells that binds to CD155 and CD112 on the surface of dendritic cells. Binding of TIGIT with CD155 or CD112 results in inhibition of T cell and NK cell activation. Antibodies and other agents that inhibit this signaling pathway have been shown to increase the immune response, especially in the case of certain cancers.
References

1. Yu, X., et al., Nat. Immunol. 2009; 10(1): 48-57.
2. Stanietsky, N., et al., Proc. Natl. Acad. Sci. 2009; 106(42): 17858-17863.